Related posts: No related posts.

The Canadian Press reports that an internal study by Industry Canada and Health Canada estimates that EU patent demands as part of the Canada – EU Trade Agreement could increase Canadian health care costs by up to $2 billion per year. The drug patent issue is viewed as a key roadblock in the CETA negotiations with the Canadian government holding off taking a position until ministers meet in November.